Vantage Biosciences
Founded 2023 · 6 employees on LinkedIn · 1 known investors
Vantage Biosciences develops clinical-stage drug therapies for retinal and other diseases, with a focus on the AOC3 target and its role in liver and eye disease. The company works with a network of preclinical and clinical experts to advance therapeutics where existing treatment options are limited.
Founders & leadership
Board
AS
Investors · 1
Companies House · registry record
View on Companies House ↗- Registered name
- VANTAGE BIOSCIENCES LTD
- Company number
- 14721262
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 10 Mar 2023
- Registered office
- 78 Pall Mall, London, SW1Y 5ES
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2025 · next due 30 Sept 2027
- Confirmation statement
- last made up to 7 Mar 2026 · next due 21 Mar 2027
Current officers · 2
- Graeme Richard Martin — director, appointed 27 Mar 2023
- Alek Safarian — director, appointed 10 Mar 2023
Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Vantage Biosciences do?
- Vantage Biosciences develops clinical-stage drug therapies for retinal and other diseases, with a focus on the AOC3 target and its role in liver and eye disease. The company works with a network of preclinical and clinical experts to advance therapeutics where existing treatment options are limited.
- Who are Vantage Biosciences's investors?
- Vantage Biosciences's investors include ALSA Ventures.